Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals) on September 19, 2016, for the month of September 2016. The filing reports on insider transactions involving the purchase of American Depositary Shares (ADSs) and warrants by company directors and senior management.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity transactions by insiders.
Material Changes and Insider Transactions
On September 16, 2016, the following transactions occurred:
- Kasbian Nuriel Chirich (Chairman): Purchased 8,960 ADSs and warrants to purchase 12,420 ADSs. Post-transaction ownership is 15.27% of outstanding ordinary shares (12.10% fully diluted).
- Dr. Shai Yarkoni (CEO): Purchased warrants to purchase 14,777 ADSs. Post-transaction ownership is 13.10% of outstanding ordinary shares (11.07% fully diluted).
- Ronen Twito (Deputy CEO/CFO): Purchased 1,452 ADSs. Post-transaction ownership is 0.09% of outstanding ordinary shares (1.96% fully diluted).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the current market price of ADSs and warrants to calculate the total value of the insider purchases.
- Confirm the total number of outstanding shares to validate the reported ownership percentages.
- Review the terms of the warrants purchased (exercise price, expiration date) to assess potential future dilution.
- Check for any concurrent press releases regarding the company's clinical pipeline or financial status not included in this specific 6-K.